Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2022-06-28 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1935 characters) and announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange, referencing an RNS Number (5070Q) and explicitly stating that the information is provided by RNS, the news service of the London Stock Exchange. This is a general regulatory announcement that does not fit the specific categories like ER, 10-K, or DIV. Since it is a standard, non-specific regulatory notification distributed via the RNS system, the most appropriate classification is the general Regulatory Filings category.
2022-06-28 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1918 characters) and contains the header 'RNS Number : 5057Q'. It announces a 'Price Monitoring Extension' for a security, which is a specific, short-form market operational update. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the FCA as a Primary Information Provider. This type of brief, operational market announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or announcement, which corresponds to the RNS code.
2022-06-28 English
Total Voting Rights Update
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and contains a date (29 April 2022). The core content is titled 'Total Voting Rights Update' and explicitly states the total number of issued ordinary shares (216,192,462) as required by the FCA's Disclosure and Transparency Rule 5.6.1. This type of mandatory, periodic disclosure regarding the total share capital and voting rights is a standard regulatory announcement. While it relates to share capital, it is not a transaction (POS) or a general capital change (SHA), but rather a mandatory disclosure of the current denominator for insider reporting. Given the RNS source and the nature of the disclosure (Total Voting Rights Update), the most appropriate classification is 'Regulatory Filings' (RNS), as it is a specific regulatory notification that doesn't fit the other specialized categories like DIV, SHA, or DIRS, and it is not an announcement of a report (RPA).
2022-04-29 English
Block Listing 6 Monthly Return
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing 6 Monthly Return' filed by Shield Therapeutics plc. This is a standard regulatory disclosure required by the London Stock Exchange (LSE) for companies to report on the issuance of shares under various employee share schemes. Since this document details changes in share capital and block listing status, it falls under the category of share issues and capital changes.
2022-03-31 English
Block Listing Application
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and contains information typical of a regulatory news service announcement from the London Stock Exchange. The content explicitly states an 'application to the London Stock Exchange for a block listing of 2,000,000 ordinary shares' and provides an expected admission date. This type of announcement, concerning the issuance of shares for an employee plan and seeking admission to trading, is a specific corporate action. While it relates to capital structure, it is primarily a formal regulatory notification disseminated via RNS. Since there is no specific code for 'Block Listing Application' and it is a general regulatory announcement distributed via RNS, the most appropriate classification is the general regulatory filing category, RNS, as it is not a full financial report (10-K, IR), a dividend notice (DIV), or a general capital change announcement (CAP/SHA) but rather a specific filing notice.
2022-03-31 English
KYE Pharmaceuticals Files Accrufer® NDS in Canada
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 3313F' and is dated March 21, 2022. It announces a specific corporate event: KYE Pharmaceuticals filing a New Drug Submission (NDS) for Accrufer® in Canada. This is a specific, material announcement disseminated via the RNS system, which is approved by the FCA to act as a Primary Information Provider. While it relates to regulatory progress (drug submission), it is not a comprehensive report (like 10-K or IR). It is a timely, specific corporate update distributed through the official regulatory news service. Given the structure (RNS header, brief announcement of a specific event, contact details, and the 'END' marker), it fits best under the general regulatory announcement category, RNS, as it is a direct regulatory news service release that doesn't fit the more specific categories like DIV, DIRS, or ER.
2022-03-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.